Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ALAA ABOUSAIF

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1235124108
CMS profile
9921
Location
ORANGE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$3,404.95

186 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,399.37 185
Education $5.58 1

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 186 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ALAA ABOUSAIF

NPI 1235124108 · CMS profile ID 9921

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

ORANGE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 186 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1235124108?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ALAA ABOUSAIF, NPI 1235124108, CMS profile ID 9921. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 186 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1235124108?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). ALAA ABOUSAIF, NPI 1235124108, CMS profile ID 9921. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 186 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1235124108?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
ALAA ABOUSAIF, NPI 1235124108, CMS profile ID 9921, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 186 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1235124108?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

186 matching records · $3,404.95 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 186 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 186.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
INTERCEPT PHARMACEUTICALS, INC. $18.8109/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053804971 CMS
AbbVie Inc. $19.1609/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996081341 CMS
Ironwood Pharmaceuticals, Inc $16.6609/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045516697 CMS
Celgene Corporation $12.1809/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016171493 CMS
GENZYME CORPORATION $20.5409/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050484811 CMS
Janssen Biotech, Inc. $25.9009/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988046201 CMS
AbbVie Inc. $3.8409/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996081339 CMS
AbbVie Inc. $28.1209/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996081337 CMS
AbbVie Inc. $23.6309/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996081335 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.0609/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996888935 CMS
Janssen Biotech, Inc. $16.4609/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988046221 CMS
NESTLE HEALTHCARE NUTRITION INC. $17.3409/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012503913 CMS
AbbVie Inc. $4.1209/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996081333 CMS
RedHill Biopharma Inc. $14.3409/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996682155 CMS
Celgene Corporation $3.9808/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016171451 CMS
AbbVie Inc. $18.4708/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996081331 CMS
AbbVie Inc. $29.1408/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996081329 CMS
AbbVie Inc. $22.9508/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996081327 CMS
QOL Medical, LLC $13.4308/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059274301 CMS
AbbVie Inc. $16.7408/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996081325 CMS
GENZYME CORPORATION $14.1008/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050484801 CMS
Celgene Corporation $16.6008/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016171421 CMS
AbbVie Inc. $29.0308/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996081323 CMS
Janssen Biotech, Inc. $9.3308/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988046239 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $21.8408/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057303441 CMS
NESTLE HEALTHCARE NUTRITION INC. $19.4108/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012503639 CMS
PFIZER INC. $16.8208/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049889559 CMS
AbbVie Inc. $28.9208/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996081321 CMS
AbbVie Inc. $12.0608/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996081319 CMS
Janssen Biotech, Inc. $17.3608/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988046247 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $26.3408/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996888937 CMS
Takeda Pharmaceuticals U.S.A., Inc. $11.0408/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055324105 CMS
Ferring Pharmaceuticals Inc. $13.5608/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044093547 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $19.9108/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057402611 CMS
AbbVie Inc. $21.6907/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996081317 CMS
AbbVie Inc. $16.3907/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996081315 CMS
Fresenius Kabi USA, LLC $24.1407/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060086929 CMS
AbbVie Inc. $5.3207/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996081313 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $22.1407/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057297865 CMS
Sandoz Inc. $25.8607/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1028926839 CMS
AbbVie Inc. $9.5007/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996081311 CMS
Celgene Corporation $17.2607/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016171353 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $23.1907/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057128033 CMS
PFIZER INC. $25.6107/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049453039 CMS
AbbVie Inc. $30.0507/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996081309 CMS
AbbVie Inc. $18.9207/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996081307 CMS
AbbVie Inc. $29.2607/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996081305 CMS
Celgene Corporation $15.6707/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016171371 CMS
AbbVie Inc. $28.9407/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996081303 CMS
Janssen Biotech, Inc. $25.9107/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988046196 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $10,232.68 134
PY2020 $4,064.78 69
PY2021 $4,217.03 160
PY2022 $3,452.00 203
PY2023 $3,404.95 186
PY2024 $36,155.95 247
PY2025 $13,201.50 251

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $934.02 1
PY2025 Principal investigator $275,142.00 70
PY2024 Principal investigator $895,988.87 155
PY2023 Principal investigator $541,023.60 39

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

71 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Recipient Eli Lilly and Company $934.02 12/17/2025 Covered Recipient Physician A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES No dispute reported 06/30/2026 1187872061
Principal investigator 1 Madrigal Pharmaceuticals $2,430.08 11/25/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248252887
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,086.00 11/20/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184263789
Principal investigator 1 Madrigal Pharmaceuticals $2,010.06 11/14/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248252591
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,043.00 10/23/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184252698
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/23/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184252700
Principal investigator 1 Madrigal Pharmaceuticals $2,010.06 09/23/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250558
Principal investigator 1 Madrigal Pharmaceuticals $9,075.38 09/18/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250229
Principal investigator 1 Madrigal Pharmaceuticals $150.00 09/18/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250233
Principal investigator 1 Genentech, Inc. $7,224.00 08/27/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211620122
Principal investigator 1 Madrigal Pharmaceuticals $4,020.12 08/21/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248871
Principal investigator 1 Boehringer Ingelheim International GmbH $1,200.00 08/20/2025 Non-covered Recipient Entity
Knowledge Research Center
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220763741
Principal investigator 1 Genentech, Inc. $7,342.00 08/20/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211620112
Principal investigator 1 Genentech, Inc. $2,736.00 08/20/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211620117
Principal investigator 1 Madrigal Pharmaceuticals $2,622.46 08/14/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248424
Principal investigator 1 Madrigal Pharmaceuticals $5,600.88 08/14/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248429
Principal investigator 1 Boehringer Ingelheim International GmbH $1,762.60 07/31/2025 Non-covered Recipient Entity
Knowledge Research Center
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220763739
Principal investigator 1 Madrigal Pharmaceuticals $1,800.00 07/31/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247761
Principal investigator 1 Madrigal Pharmaceuticals $750.00 07/31/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247765
Principal investigator 1 Madrigal Pharmaceuticals $1,837.05 07/31/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247769
Principal investigator 1 Bausch Health US, LLC $1,358.00 07/23/2025 Non-covered Recipient Entity
Knowledge Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224842383
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,391.40 07/17/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184217196
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,244.20 07/17/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184217198
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,350.00 07/17/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184217200
Principal investigator 1 Boehringer Ingelheim International GmbH $2,000.00 07/16/2025 Non-covered Recipient Entity
Knowledge Research Center
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220763733
Principal investigator 1 Boehringer Ingelheim International GmbH $2,500.00 07/16/2025 Non-covered Recipient Entity
Knowledge Research Center
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220763735
Principal investigator 1 Boehringer Ingelheim International GmbH $12,500.00 07/16/2025 Non-covered Recipient Entity
Knowledge Research Center
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220763737
Principal investigator 1 Madrigal Pharmaceuticals $9,668.70 07/10/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246813
Principal investigator 1 Madrigal Pharmaceuticals $11,505.38 07/10/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246818
Principal investigator 1 Madrigal Pharmaceuticals $200.00 07/10/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246822
Principal investigator 1 Madrigal Pharmaceuticals $15,150.38 06/24/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245978
Principal investigator 1 Madrigal Pharmaceuticals $300.00 06/24/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245982
Principal investigator 1 Madrigal Pharmaceuticals $3,674.10 06/24/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245986
Principal investigator 1 Madrigal Pharmaceuticals $2,622.46 06/24/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245989
Principal investigator 1 Bausch Health US, LLC $377.00 06/02/2025 Non-covered Recipient Entity
Knowledge Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224842388
Principal investigator 1 Bausch Health US, LLC $1,686.00 06/02/2025 Non-covered Recipient Entity
Knowledge Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224842391
Principal investigator 1 Bausch Health US, LLC $2,111.00 06/02/2025 Non-covered Recipient Entity
Knowledge Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224842399
Principal investigator 1 Madrigal Pharmaceuticals $2,365.96 05/28/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244531
Principal investigator 1 Madrigal Pharmaceuticals $5,052.54 05/22/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244091
Principal investigator 1 Madrigal Pharmaceuticals $2,430.08 05/15/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248243500
Principal investigator 1 Madrigal Pharmaceuticals $2,365.96 04/08/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248241725
Principal investigator 1 Genentech, Inc. $8,428.00 04/04/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211620105
Principal investigator 1 Bausch Health US, LLC $1,571.00 04/02/2025 Non-covered Recipient Entity
Knowledge Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224842395
Principal investigator 1 Boehringer Ingelheim International GmbH $104.94 03/25/2025 Non-covered Recipient Entity
Knowledge Research Center
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220763711
Principal investigator 1 Boehringer Ingelheim International GmbH $179.82 03/25/2025 Non-covered Recipient Entity
Knowledge Research Center
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220763713
Principal investigator 1 Boehringer Ingelheim International GmbH $730.00 03/25/2025 Non-covered Recipient Entity
Knowledge Research Center
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220763715
Principal investigator 1 Boehringer Ingelheim International GmbH $549.63 03/25/2025 Non-covered Recipient Entity
Knowledge Research Center
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220763717
Principal investigator 1 Boehringer Ingelheim International GmbH $262.20 03/25/2025 Non-covered Recipient Entity
Knowledge Research Center
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220763719
Principal investigator 1 Boehringer Ingelheim International GmbH $4.05 03/25/2025 Non-covered Recipient Entity
Knowledge Research Center
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220763721
Principal investigator 1 Boehringer Ingelheim International GmbH $35.49 03/25/2025 Non-covered Recipient Entity
Knowledge Research Center
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220763723
Principal investigator 1 Boehringer Ingelheim International GmbH $35.49 03/25/2025 Non-covered Recipient Entity
Knowledge Research Center
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220763725
Principal investigator 1 Boehringer Ingelheim International GmbH $35.49 03/25/2025 Non-covered Recipient Entity
Knowledge Research Center
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220763727
Principal investigator 1 Boehringer Ingelheim International GmbH $35.49 03/25/2025 Non-covered Recipient Entity
Knowledge Research Center
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220763729
Principal investigator 1 Boehringer Ingelheim International GmbH $70.50 03/25/2025 Non-covered Recipient Entity
Knowledge Research Center
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220763731
Principal investigator 1 Genentech, Inc. $4,816.00 03/21/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211620092
Principal investigator 1 Boehringer Ingelheim International GmbH $1.20 03/14/2025 Non-covered Recipient Entity
Knowledge Research Center
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220763709
Principal investigator 1 Madrigal Pharmaceuticals $17,934.63 03/06/2025 Non-covered Recipient Entity
KNOWLEGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240432
Principal investigator 1 Genentech, Inc. $7,884.00 02/26/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211620100
Principal investigator 1 Genentech, Inc. $14,448.00 02/12/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211620085
Principal investigator 1 Bausch Health US, LLC $377.00 02/07/2025 Non-covered Recipient Entity
Knowledge Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224842352
Principal investigator 1 Bausch Health US, LLC $1,234.00 02/07/2025 Non-covered Recipient Entity
Knowledge Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224842360
Principal investigator 1 Bausch Health US, LLC $1,358.00 02/07/2025 Non-covered Recipient Entity
Knowledge Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224842364
Principal investigator 1 Bausch Health US, LLC $1,358.00 02/07/2025 Non-covered Recipient Entity
Knowledge Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224842379
Principal investigator 1 Madrigal Pharmaceuticals $2,622.46 02/06/2025 Non-covered Recipient Entity
KNOWLEGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248239258
Principal investigator 1 Genentech, Inc. $25,120.00 02/05/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211620077
Principal investigator 1 Madrigal Pharmaceuticals $9,225.38 01/09/2025 Non-covered Recipient Entity
KNOWLEGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248238207
Principal investigator 1 Madrigal Pharmaceuticals $17,830.38 01/09/2025 Non-covered Recipient Entity
KNOWLEGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248238211
Principal investigator 1 Bausch Health US, LLC $377.00 01/08/2025 Non-covered Recipient Entity
Knowledge Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224842356
Principal investigator 1 Bausch Health US, LLC $1,639.00 01/08/2025 Non-covered Recipient Entity
Knowledge Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224842367
Principal investigator 1 Bausch Health US, LLC $2,111.00 01/08/2025 Non-covered Recipient Entity
Knowledge Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224842372
Principal investigator 1 Bausch Health US, LLC $2,111.00 01/08/2025 Non-covered Recipient Entity
Knowledge Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224842375